Eisai, Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai's MORAb-202 Antibody Drug Conjugate
- Written by ACN Newswire - Press Releases
Tokyo and New York, Jun 18, 2021 - (JCN Newswire) - Eisai Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the companies have entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC).
MORAb-202 is Eisai's first ADC
Read more //?#